Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Drops By 18.2%

Monopar Therapeutics Inc. (NASDAQ:MNPR) saw a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 22,000 shares, a decline of 18.2% from the November 15th total of 26,900 shares. Based on an average daily volume of 1,240,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.7% of the company’s shares are short sold.

Monopar Therapeutics Trading Up 4.7 %

Monopar Therapeutics stock traded up $1.13 during trading on Friday, hitting $25.38. 47,461 shares of the company were exchanged, compared to its average volume of 638,553. The company has a market capitalization of $133.96 million, a P/E ratio of -12.88 and a beta of 1.23. The business’s 50 day moving average is $15.94 and its 200 day moving average is $7.86. Monopar Therapeutics has a 52 week low of $1.40 and a 52 week high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Equities analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insider Transactions at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was acquired at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the purchase, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 34.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms have issued reports on MNPR. HC Wainwright increased their price target on Monopar Therapeutics from $6.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Rodman & Renshaw assumed coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 price objective for the company.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.